Scientists spy on immune cells to unlock melanoma treatment secrets
NCT ID NCT02626065
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This study involved 32 people with advanced melanoma who were being treated with Anti-PD1 drugs (Nivolumab). The goal was to track changes in different immune cells (like dendritic cells and T cells) before and during treatment. By comparing those who responded well to those who did not, researchers hoped to find clues to improve treatment success rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
Conditions
Explore the condition pages connected to this study.